Gastric Cancer Treatment: Navigating Adjuvant Radiochemotherapy and Improving Tolerability
"A Deep Dive into Operable Gastric Cancer: Understanding Prognostic Factors and the Role of Tolerability in Adjuvant Treatment"
Gastric cancer remains a significant global health challenge, ranking as the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. While advancements in treatment strategies have improved outcomes for some, the prognosis for many patients remains poor, highlighting the urgent need for more effective and tolerable therapies.
Surgery to remove the tumor and affected lymph nodes is a key part of gastric cancer treatment. After surgery, adjuvant therapies like chemoradiotherapy (CRT) can help reduce the risk of cancer recurrence. However, adjuvant CRT can be difficult for patients to tolerate due to its side effects, and not all patients benefit equally.
A recent study published in Neoplasma sheds light on the complexities of treating operable gastric cancer with adjuvant CRT. The study, which retrospectively analyzed data from 723 patients across multiple medical centers in Turkey, aimed to evaluate the tolerability and toxicity of adjuvant CRT and identify factors that influence prognosis. This article breaks down the study's key findings and what they mean for patients and their treatment journeys.
A Fifth-Leading Global Cancer Burden
In 2020, gastric cancer accounted for 1,089,103 new cases worldwide, making it the fifth most common cancer globally. In the same year, the disease caused an estimated 769,000 deaths. Roughly 60% of cases occur in Asia, and about 80% of deaths occur in low- and middle-income countries. Beyond the common adenocarcinomas, gastric cancer also encompasses gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas.
Guidelines, Diagnosis, and the Gaps That Remain
Treatment is guided by frameworks such as the Japanese Gastric Cancer Treatment Guidelines (6th edition, 2021), which currently do not render either more extensive or more limited lymphadenectomies inappropriate. Diagnosis and risk assessment rely heavily on endoscopy: standard and magnifying narrow-band imaging endoscopy are useful for diagnosing H. pylori gastritis and precancerous conditions. The approach, however, has recognized limitations, including biomarker assessment, where histologic evaluation of HER2 may be constrained by tissue sampling and spatial heterogeneity, prompting interest in radiomics models for preoperative classification. Experts such as David Goldstein have also highlighted the limitations of current immunotherapy approaches and the need to reassess strategies for targeting gastric cancer.
From Prevalence Peak to the Precancerous Cascade
Gastric cancer has historically been one of the most prevalent cancers and, combined with a high mortality, has ranked among the leading causes of cancer death. Its incidence has seen a steady decline since the 1930s, which may be partially attributable to the advent of widespread food refrigeration that replaced smoking meat as a means of preservation. Foundational understanding of the disease rests on the gastric precancerous cascade, involving conditions such as gastric atrophy, intestinal metaplasia, and dysplasia, often in the setting of H. pylori infection. Family history of cancer in first-degree relatives may also inform the risk of gastric cancer and preneoplastic lesions.
Key Findings: Tolerability Matters
The research team, consisting of M. Kucukoner and colleagues, collected and analyzed data from eight medical centers in Turkey. Their work provides valuable insights into the challenges and opportunities in gastric cancer treatment. The study population included patients with stage IB-IV (M0) operable gastric cancer who received adjuvant CRT between 2003 and 2010. The researchers examined a variety of factors, including patient demographics, tumor characteristics, treatment regimens, and survival outcomes.
- Tolerability is Key: Patients who tolerated adjuvant CRT had better survival rates.
- Stage Matters: Advanced tumor stage was associated with poorer outcomes.
- Lauren Classification: Intestinal-type gastric cancer showed better prognosis compared to the diffuse type.
- D2 Dissection: More extensive lymph node removal (D2 dissection) improved survival.
Genetics, Precancerous Risk, and Ongoing Surveillance Research
Recent research continues to refine the genetic picture of gastric cancer: the NCI's Genetics of Gastric Cancer summary covers hereditary cancer syndromes, including hereditary diffuse gastric cancer and other associated genes, with updates as recent as May 2025. A systematic review and meta-analysis has also examined the risk of diffuse-type gastric cancer following a diagnosis with gastric precancerous lesions, noting that gastric cancer is the fifth-leading cause of cancer incidence. Complementing this, studies report on the prevalence of gastric precancerous conditions, reflecting that gastric carcinoma is a common malignant disease with an unfavorable prognosis when diagnosis is late.
Late Diagnosis and Uneven Treatment Gains
A central failure of gastric cancer care is late diagnosis: most children and adults with stomach cancer have no early symptoms or signs until the cancer has advanced, and anemia is one of the most common signs of advanced disease. This is mirrored in real cases, such as a 60-year-old man presenting with abrupt weight loss, dyspepsia, post-meal bloating, and loss of appetite worsening over three months, alongside a family history of gastric cancer. Treatment gains are also unevenly distributed: although immunotherapy has changed the cancer treatment landscape, its benefits remain unevenly distributed among patients with gastric cancer, and immune checkpoint blockade does not help all patients equally.
Robotic Versus Laparoscopic Surgery and Regional Differences
Surgical comparisons center on safety and oncologic soundness: robotic gastrectomy has been described as an oncologically sound alternative to laparoscopic resections for the treatment of early-stage gastric cancers, with studies comparing robot versus laparoscopic gastrectomy on measures such as complications and surgical stress. Enhanced recovery after surgery protocols are being evaluated alongside these approaches. Regional differences are equally striking: the incidence of gastric cancer in Japan is four times higher than in the UK, and it usually arises in a stomach with corpus-predominant or pangastritis that has undergone extensive atrophy and intestinal metaplasia.
Improving Tolerability: The Path Forward
The study underscores the need to find ways to improve the tolerability of adjuvant CRT for gastric cancer patients. Strategies such as dose modification, supportive care interventions, and the use of less toxic chemotherapy regimens may help more patients complete the full course of treatment and achieve better outcomes. Ongoing research is exploring novel approaches to personalize adjuvant therapy based on individual patient characteristics and tumor biology. By tailoring treatment to the specific needs of each patient, we can minimize side effects and maximize the benefits of adjuvant therapy, ultimately improving survival and quality of life for individuals with operable gastric cancer.
Expert Consensus, Guideline Quality, and Unresolved Puzzles
Expert discussions, such as those from the 12th ESMO/World Congress on Gastrointestinal Cancer in Barcelona (2010), led by E. van Cutsem, summarize recommendations and expert opinion on gastric cancer, including a detailed epidemiological analysis that the authors describe as revealing many puzzling features. Commentators also stress that to improve the quality of gastric cancer guidelines, the process should involve not only development but also validation. In the era of targeted therapy and individualized treatment strategies, novel treatments remain necessary, as oesophageal and gastric cancers continue to be leading causes of cancer-related mortality.
Declining Trends in Some Regions, Rising Risks Without Prevention
Future projections are mixed across regions. In Korea, the risk of gastric cancer death has decreased since the 1919 birth cohort for both genders, and these decreasing trends have been extrapolated into the future for predictions. However, without adequate prevention, gastric cancer incidence may rise sharply, since gastric cancer ranks as the fifth most common cancer globally and remains a significant cause of cancer-related deaths worldwide. Treatment research continues to focus on reducing recurrence: despite curative-intent surgery, the risk of recurrence is high, and perioperative treatment may improve rates of complete surgical resection and reduce the rate of recurrence.
Molecular Drivers and Systemic Disease Mechanisms
Gastric cancer is understood not only surgically but at a systemic and molecular level. Research highlights the gastrin system, noting that agents such as PAS block the trophic effects of gastrin and disrupt tumor growth, which suggests the gastrin system has broad carcinogenic significance. The disease may also exploit little-known metabolic molecules: research from Keio University in Japan reports that D-serine appears to act as a molecule that can disable the immune system and accelerate tumor growth in gastric cancer. Additional lines of investigation explore TRP channels in gastric cancer, described as offering new hopes and clinical perspectives.
Real-World Outcomes and Pandemic Disruption
The impact of gastric cancer is best appreciated through real-world experience rather than trials alone. Evidence from Henan, China, shows that patients treated with apatinib outside clinical trials achieved efficacy results similar to, and in some cases better than, those from pivotal trials, even in heavily pre-treated patients. Case reports also document advanced gastric cancer with multiple skin metastases where immunotherapy provided significant relief. The COVID-19 pandemic underscored how real-world disruption affects outcomes: a nationwide, real-world study provides robust evidence that COVID-19 reduced survival rates for Japanese patients with gastric cancer by disrupting diagnosis and treatment.